Chun Kun Lee

US Patent:

D473420, Apr 22, 2003

Filed:

Aug 22, 2002

Appl. No.:

29/166114

Inventors:

Yi M Lo - Cranford NJ 07016
Chun K Lee - Towaco NJ 07082

International Classification:

3100

US Classification:

D 7376

US Patent:

D486040, Feb 3, 2004

Filed:

Mar 12, 2003

Appl. No.:

29/177563

Inventors:

Yi Ming Lo - Cranford NJ 07016
Chun Kai Lee - Towaco NJ 07082

International Classification:

3100

US Classification:

D 7665

US Patent:

8642357, Feb 4, 2014

Filed:

Oct 22, 2009

Appl. No.:

12/604192

Inventors:

Jack A. Elias - Woodbridge CT, US
Chun Geun Lee - New Haven CT, US

Assignee:

Yale University - New Haven CT

International Classification:

G01N 33/53
A61K 39/395
C12Q 1/68
C12N 15/11
C12N 15/113
A61K 38/00

US Classification:

436547, 436543, 436544, 436545, 436546, 436548, 4241301, 4241411, 4241421, 4241351, 4241781, 514 44 A, 514 18

Abstract:

The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.

US Patent:

20100247538, Sep 30, 2010

Filed:

May 29, 2008

Appl. No.:

12/601778

Inventors:

Jack A. Elias - New Haven CT, US
Chun Geun Lee - Orange CT, US

International Classification:

A61K 39/395
A61K 31/713
A61K 31/7088
A61K 31/7105
A61K 38/02
A61P 11/00

US Classification:

4241351, 4241301, 4241411, 4241331, 514 44 A, 514 44 R, 514 189, 514 11

Abstract:

The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL-18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL-18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.

US Patent:

20230046834, Feb 16, 2023

Filed:

Nov 19, 2020

Appl. No.:

17/778375

Inventors:

- Providence RI, US
Chun Geun Lee - Woodbridge CT, US
Suchitra Kamle - Providence RI, US

International Classification:

C07K 16/28
C07K 16/40
A61K 39/395
A61K 45/06
A61P 35/00

Abstract:

Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule CTLA4. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and CTLA4 antibodies, alone or in combination. Methods of treating tumors, including lung and brain tumors by administering the bispecific antibodies described herein are also provided.

US Patent:

20210128595, May 6, 2021

Filed:

Aug 17, 2018

Appl. No.:

16/639462

Inventors:

- Providence RI, US
Chun Geun LEE - Woodbridge CT, US
Chang-Min LEE - Warwick RI, US

International Classification:

A61K 31/7034

Abstract:

Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.

US Patent:

20210009712, Jan 14, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943320

Inventors:

- Providence RI, US
Chun Geun LEE - Woodbridge CT, US
Chuan Hua HE - Madison CT, US
Bing MA - Branford CT, US
Suchitra KAMLE - Providence RI, US
Chang-Min LEE - Warwick RI, US

International Classification:

C07K 16/40
A61P 35/04
A61K 45/06
C07K 16/28

Abstract:

It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

US Patent:

20200354474, Nov 12, 2020

Filed:

Jul 27, 2020

Appl. No.:

16/939265

Inventors:

- Providence RI, US
Chun Geun LEE - Woodbridge CT, US
Chuan Hua HE - Madison CT, US
Bing MA - Branford CT, US
Suchitra KAMLE - Providence RI, US
Chang-Min LEE - Warwick RI, US

International Classification:

C07K 16/40
A61P 31/04
A61P 29/00
A61P 35/04
A61P 35/00
A61P 19/02
G01N 33/53
A61P 3/04
C07K 16/18

Abstract:

Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.